Journal
DIAGNOSTICS
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics11122196
Keywords
KRAS G12C; liquid biopsy; clonal evolution; non-small-cell lung cancer; circulating tumor DNA
Categories
Ask authors/readers for more resources
Liquid biopsies, specifically real-time polymerase chain reaction and next-generation sequencing, were compared to track the KRAS G12C mutation at disease progression onset. 24% of patients acquired the KRAS G12C mutation at the time of progressive disease, and all patients with this mutation in tissue samples became negative in circulating tumor DNA at progressive disease. Real-time PCR assay Idylla could be a suitable approach to match patients with interventional biomarker-targeted therapies based on the assessment of plasma KRAS G12C mutation as a druggable target.
Although molecular profiling at diagnosis has traditionally relied on direct sampling of neoplastic tissue, cancer clonal evolution represents a critical obstacle to use primary tissue biopsies to guide clinical decision-making at the time of progressive disease. Liquid biopsies might offer enormous advantages over tissue biopsies, tracking in real-time temporal-based tumor dynamics following each line of treatment. Here, we compared two liquid biopsy assays, specifically real-time polymerase chain reaction and next-generation sequencing, to track the KRAS G12C mutation at onset of progression from previous lines of therapy. The KRAS G12C mutation was acquired at the time of progressive disease in 24% of patients. Furthermore, all patients with KRAS G12C mutation-positive tissue became negative in ctDNA at progressive disease. The presence of other somatic mutations in all these samples confirmed the tumor origin of the circulating DNA. This pilot study suggests that in the assessment of the plasma KRAS G12C mutation as a druggable target, real-time PCR assay Idylla might be a suitable approach to better match patients to interventional biomarker-targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available